Achilles Therapeutics plc ACHL
Set alert
At close · Mar 20
52-week range unavailable
- YTD
- +29.82%
- 1 year
- +14.73%
- Open
- 1.48
- Prev close
- 1.48
- Mkt cap
- 60.83M
- Vol
- 1.20M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.48
- High
- 1.48
- Forward P/E
- -0.61
- Beta
- 1.34
- Short ratio
- 1.69
- Inst. own
- 59.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.02
- 200-d avg
- 0.91881
- 1y target
- 0.00
6M chart
Events in this range
- Nov 14, 2024Earnings: -0.48; estimate -0.41; surprise -17.07%
Signals (18)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Mar 18, 2025 | 1 year ago |
| RSI: Overbought | Mar 13, 2025 | 1 year ago |
| RSI: Overbought | Feb 26, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 4, 2025 | 1 year ago |
| RSI: Overbought | Feb 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 17, 2025 | 1 year ago |
| RSI: Overbought | Dec 30, 2024 | 1 year ago |
| SMA: Bullish | Dec 24, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
| RSI: Overbought | Dec 24, 2024 | 1 year ago |
| RSI: Oversold | Dec 17, 2024 | 1 year ago |
| SMA: Bearish | Dec 11, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 11, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 7, 2024 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2024 | 2 years ago |
| RSI: Overbought | Oct 3, 2024 | 2 years ago |
| RSI: Overbought | Sep 26, 2024 | 2 years ago |
Key statistics
- Market cap
- 48.70M
- Enterprise value
- -46.68M
- Trailing P/E
- 0.00
- Forward P/E
- -0.61
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.33
- EPS (TTM)
- -1.66
- Beta
- 1.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -30.14M
- Total cash
- 95.11M
- Total debt
- 4.46M
- Return on equity
- -44.22%
- Shares outstanding
- 41.09M
- Short % of float
- 0.63%
- 50-day average
- 1.02
- 200-day average
- 0.91881
Analyst view
Consensus: buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.41 | -0.48 | -0.07 | -17.07% |
| Aug 14, 2024 | Jun 1, 2024 | -0.41 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.41 | -0.41 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.46 | -0.30 | +0.16 | +34.78% |
| May 8, 2024 | Mar 1, 2024 | -0.46 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 5, 2024 | Chardan Capital | main | Buy | Buy |
| Apr 5, 2024 | Piper Sandler | down | Overweight | Neutral |
| Dec 14, 2023 | B of A Securities | down | Buy | Underperform |
| Aug 7, 2023 | Chardan Capital | reit | Buy | Buy |
| May 11, 2023 | Chardan Capital | main | Buy | Buy |
| Dec 7, 2022 | Chardan Capital | main | — | Buy |
About Achilles Therapeutics plc
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- achillestx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ACHL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Syncona Portfolio Ltd | 26.98% | 11,086,909 | 12.64M | Sep 29, 2024 |
| BML Capital Management, LLC | 9.98% | 4,100,002 | 4.67M | Sep 29, 2024 |
| Fcpm III Services B.v. | 5.82% | 2,390,050 | 2.72M | Sep 29, 2024 |
| Redmile Group, LLC | 3.91% | 1,608,089 | 1.83M | Sep 29, 2024 |
| Vestal Point Capital, LP | 3.65% | 1,500,000 | 1.71M | Sep 29, 2024 |
| Ikarian Capital, LLC | 3.51% | 1,443,181 | 1.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 21,590 | 24.61K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 100 | 113 | Sep 29, 2024 |